Brooks Automation

16th Annual Needham Virtual Technology & Media Conference

May 20, 2021

Safe Harbor Statement

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. Further discussions of risk factors are available in the Company's most recent SEC filings, including the annual report on Form 10-K for the fiscal year ended September 30, 2020 and any subsequent quarterly reports on Form 10-Q. The Company assumes no obligation to update the information in this presentation.

Regulation G

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Brooks business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant GAAP amount are provided as a separate presentation on the Company's website. All financial projections throughout this presentation, other than ROIC, exclude amortization of intangibles, restructuring expense and other special charges.

© 2021 Brooks Automation, Inc. • Proprietary Information

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Separation Announcement
- Building on two strong platforms – Life Sciences and Semiconductor
- Model for profitable growth

© 2021 Brooks Automation, Inc. • Proprietary Information

A Strong Track Record of Growth and Margin Expansion

Brooks Overview

$1B Revenue, +20% YtY
LTM 3/31/21

$287M Revenue , +30% YtY
Q2 FY'21

~ 3,400 Global Employees

Sales in 50 Countries

NASDAQ: BRKS

Sept 30 Year-End

Dividend $0.40/share per year



© 2021 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measure – see Regulation G statement on pg.2

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Separation Announcement
- Building on two strong platforms – Life Sciences and Semiconductor
- Model for profitable growth

© 2021 Brooks Automation, Inc. • Proprietary Information

Taking the Next Step in Value Creation



Growth (YtY)	**+18%**	**+20%**	**+20%**
Gross Margin*	**34%**	**40%**	**46%**

© 2021 Brooks Automation, Inc. • Proprietary Information

*Gross Margin – Non-GAAP financial measure
Note: LTM as of 3/31/21, which does not include Precise Automation, acquired on 4/29/21

Introducing Two Highly Focused Market-Leading Companies

New Life Sciences Co

- Sample Management Products
- Sample Repository Services
- Genomic Services

- CEO, Steve Schwartz; CFO, Lindon Robertson
- ~2,300 Global Employees
- LTM Metrics*:
  - Revenue: $449M, +22% YtY
  - Gross Margin: 49%
  - Adjusted EBITDA: 22%, +8.2pts YtY

New Brooks Automation



- Semiconductor & Multi-Market Automation
- Contamination Control Solutions

- CEO, Dave Jarzynka; CFO, Dave Pietrantoni
- ~1,100 Global Employees
- LTM Metrics*:
  - Revenue: $553M, +19% YtY
  - Gross Margin: 43%
  - Adjusted EBITDA: 22%, +4.5pts YtY

Both with strong balance sheets and attractive investment opportunities

© 2021 Brooks Automation, Inc. • Proprietary Information
*LTM as of 3/31/2021, which does not include Precise Automation, acquired on 4/29/21; reflects non-GAAP gross margin and adjusted EBITDA

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Separation Announcement
- Building on two strong platforms – **Life Sciences** and Semiconductor
- Model for profitable growth

© 2021 Brooks Automation, Inc. • Proprietary Information

Life Sciences Business

Market-leading Portfolio With Proven Value

Serving a ~$10B Market in Sample Storage and Genomics

Products

- Consumables & Instruments
- Ultra Cold Automated Stores
- Cryo Automation

Services

- Genomic Services
- Sample Repository Solutions
- Informatics

Life Sciences Revenue



© 2021 Brooks Automation, Inc. • Proprietary Information

Life Sciences Business

Diverse Revenue Profile Aligned for Higher Growth

Products* 37%



Services* 63%

Positioning and Strategy

Best-in-Class Solutions
- ✓ Science
- ✓ Technology

Quality & Integrity
- ✓ Sample assets
- ✓ Expert analysis

Efficiency in Workflow
- ✓ Fast Turnaround Time
- ✓ Global Footprint

Aligned in Key Growth Markets
- ✓ Drug discovery and R&D
- ✓ Cell and Gene Therapy

© 2021 Brooks Automation, Inc. • Proprietary Information

*LTM as of 3/31/2021

Strong Foundation for Existing and Future Growth Vectors

1. Strong Foundation of Organic Growth

✓

- Differentiated sample repository & genomics services
- Market leadership in Cryo for Cell & Gene Therapy (C&GT) and other complex applications
- Turnkey solutions for R&D and manufacturing

2. Accelerate Capabilities for Novel Modalities

+

- Genomics is the center of C&GT, mRNA, and viral vector-based solutions

3. Insights for Drug Discovery and Development

+

- Leverage Sample Repository and customer network
- Data extraction, informatics, sourcing of samples

Customer Base of Leading Institutions

AstraZeneca, Pfizer, MERCK, Intermountain Healthcare, gsk, Fukushima University, J&J, Catalent, Bristol-Myers Squibb, VERTEX, novo nordisk, Mount Sinai, NOVARTIS, teva, Kite, National Cancer Institute, Janssen, Lilly, GRAIL, MAYO CLINIC, Celgene, VANDERBILT, GILEAD, University of Cambridge

© 2021 Brooks Automation, Inc. • Proprietary Information

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Separation Announcement
- Building on two strong platforms – Life Sciences and **Semiconductor**
- Model for profitable growth

© 2021 Brooks Automation, Inc. • Proprietary Information

Winning Platforms Building on Secular Industry Tailwinds

Balanced Portfolio Across High-Growth Segments

Semiconductor Automation

- Vacuum Systems & Robots
- Advanced Packaging Solutions

Contamination Control

- FOUP Clean
- EUV POD Clean
- Reticle Storage

Multi-market Automation

- Collaborative Robots
- Integrated Vision Technology

Semiconductor Solutions Revenue



© 2021 Brooks Automation, Inc. • Proprietary Information

High Value Portfolio Serving Strong Market Drivers

Market Drivers of WFE Capex

Volume Demand

- New chip factory lines
- Capacity build-out

Chip Complexity

- More process steps
- Contamination vulnerability

Positioned to Grow with Complexity Multiplier

Positioning and Strategy

Global Semiconductor Leadership

- ✓ Partnership position with customer engineering
- ✓ Contaminant free automation in vacuum environment
- ✓ Contamination control solutions for wafers and reticles

Innovative Application Solutions

- ✓ Precision motion control
- ✓ Proven quality and reliability
- ✓ Yield enhancement
- ✓ Wafer flow management

Emerging Collaborative Automation



- ✓ Leading collaborative motion expertise
- ✓ Expanding into multiple markets
- ✓ Work flow management

© 2021 Brooks Automation, Inc. • Proprietary Information • “WFE” = Wafer fabrication equipment

Growth Opportunities Will Leverage Existing Strengths

1. Strong Foundation of Organic Growth

- **#1 Leadership position** in Semiconductor Vacuum Automation and Contamination Control
- **Key enabler** of customer process advantages applicable **to all fabs for all technology nodes**
- Robust near- and long-term industry growth projections

2. Expanding Automation Capabilities

- **Deep engineering expertise** allows for **expanding to adjacent applications** and end markets
- Acquisition of Precise Automation
  - Leadership in collaborative robots
  - Customers in lab automation, semi, and electronics

Industry Leading Customers

© 2021 Brooks Automation, Inc. • Proprietary Information

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Separation Announcement
- Building on two strong platforms – Life Sciences and **Semiconductor**
- Model for profitable growth

© 2021 Brooks Automation, Inc. • Proprietary Information

Disciplined Approach to Capital Deployment

Key Principles

1. Extend leadership in core markets
2. Advance the rapid growth of each business with organic and acquisition investments
3. Drive margin expansion
4. Utilize balanced and disciplined capital deployment

> $1B Capital Deployment Over Past 5 Years



© 2021 Brooks Automation, Inc. • Proprietary Information

Continuous Portfolio Enhancement for Value and Higher Growth

Acquisitions

Life Sciences	>$800M
Semi	>$100M

2011-2012

- RTS for $3M
- Nexus for $85M
- Crossing Automation for $59M
- Divested of Contract Manufacturing for $78M

2013-2014

- Matrical for $9M
- 22% of BioCision for $4M
- DMS for $32M
- Divested of Granville-Phillips instrumentation for $87M

2015-2016

- FluidX for $16M
- BioStorage Technologies for $125M
- Contact for $7M

2017-2018

- BioCision add'l $11M
- PBMMI for $34M
- FreezerPro software for $5M
- 4titude Ltd. for $66M
- BioSpeciMan for $5M
- Tec-Sem for $16M

2019 - 2020

- GENEWIZ for $450M
- RURO for $15M
- Divested Semi Cryo for $675M

FY2021

- Trans-Hit Biomarkers for $15M
- Precise Automation for $70M

10 years, >20 transactions, with ROIC focus

© 2021 Brooks Automation, Inc. • Proprietary Information

Guidance As Provided May 10, 2021
Continuing operations

$M except EPS	Q1'21	Q2'21	Guidance for Q3'21 Ending 6/30/21	Approximate 12 Mo Ending 6/30/21 at Mpt of Guidance
Brooks Total Revenue *Semiconductor Solutions* *Life Science*	**$250** *$131* *$118*	**$287** *$157* *$130*	**$300-320** *$172-182* *$128-138*	**~$1.1B** *~$600M* *~$490M*
Adjusted EBITDA*	$58	$71	$73-82	~$260M
Non-GAAP EPS*	$0.47	$0.61	$0.65-0.75	$2.25
Dividends/share Returned to Shareholders	$0.10	$0.10	$0.10**	$0.40**

* Non-GAAP financial measure

** The Board of Directors approved a dividend of $0.10 per share, payable on June 25, 2021 to stockholders of record on June 4, 2021.

Note: Until the culmination of the announced separation, results and guidance will continue to reflect total Brooks as a single entity.

© 2021 Brooks Automation, Inc. • Proprietary Information •

IN SUMMARY

Two High Performance Businesses. Positioned for Profitable Growth and Further Investment

Leadership Positions in Two Strong Markets

- Semiconductor and Automation Solutions
- Life Sciences Sample Management and Genomics

Attractive Long Term Financial Model

- Two profitable growth businesses
- Significant operating leverage for increased profits and cash

Track Record of Effective Capital Deployment

- Capturing opportunity for growth & value through acquisitions
- 10 years, >20 transactions, with ROIC focus

© 2021 Brooks Automation, Inc. • Proprietary Information

Brooks

Thank You

Non-GAAP Reconciliation Appendix

Non-GAAP Annual Operating Performance
Continuing Operations

$ millions, except EPS

Total Brooks

	FY15	FY16	FY17	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Revenue	407	434	527	632	781	897	834	1,003
Gross profit*	139	161	203	253	327	391	350	461
*Gross profit margin**	*34.1 %*	*37.2 %*	*38.5 %*	*40.0 %*	*41.9 %*	*43.6 %*	*42.0 %*	*46.0 %*
R&D expenses	46	44	40	47	56	59	59	62
SG&A expenses*	96	104	120	141	181	210	197	223
Operating income *	(3)	13	43	65	90	122	95	176
*Operating margin**	*(0.8)%*	*2.9 %*	*8.2 %*	*10.3 %*	*11.6 %*	*13.6 %*	*11.4 %*	*17.6 %*
Other income (expense)*	2	(1)	(2)	(11)	(22)	(3)	(11)	(0)
Tax benefit (provision)*	5	4	(10)	(9)	(13)	(26)	(17)	(37)
JV and noncontrolling interests*	(1)	(1)	(0)	-	-	-	-	-
Net income*	3	15	31	45	55	93	66	138
*Net income margin**	*0.8 %*	*3.4 %*	*5.9 %*	*7.2 %*	*7.1 %*	*10.4 %*	*7.9 %*	*13.8 %*
Diluted Non-GAAP EPS - Continuing Ops*	0.05	0.21	0.44	0.64	0.76	1.26	0.91	1.87
Adjusted EBITDA*	18	34	68	93	128	161	134	223

© 2021 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measure

Non-GAAP Annual Operating Performance – Business Segments Continuing Operations

$ millions

	Brooks Semiconductor Solutions				
	FY18	**FY19**	**FY20**	**LTM 3/31/20**	**LTM 3/31/21**
Revenue	435	447	509	465	553
Gross profit*	178	185	211	188	240
*Gross profit margin**	*40.9 %*	*41.5 %*	*41.4 %*	*40.4 %*	*43.4 %*
Operating expenses	116	115	128	122	134
Operating income *	63	70	83	66	106
*Operating margin**	*14.4 %*	*15.7 %*	*16.3 %*	*14.1 %*	*19.2 %*

	Brooks Life Sciences				
	FY18	**FY19**	**FY20**	**LTM 3/31/20**	**LTM 3/31/21**
Revenue	197	334	389	369	449
Gross profit*	75	142	181	162	221
*Gross profit margin**	*38.0 %*	*42.4 %*	*46.5 %*	*44.0 %*	*49.2 %*
Operating expenses	71	121	142	135	150
Operating income *	4	21	38	27	71
*Operating margin**	*1.9 %*	*6.2 %*	*9.8 %*	*7.3 %*	*15.8 %*

© 2021 Brooks Automation, Inc. • Proprietary Information
* Non-GAAP financial measure

Non-GAAP Quarterly Operating Performance
Continuing Operations

$ millions, except EPS

	Total Brooks				
	Q2'20	**Q3'20**	**Q4'20**	**Q1'21**	**Q2'21**
Revenue	220	220	246	250	287
Gross profit*	93	96	115	116	135
*Gross profit margin**	*42.2 %*	*43.5 %*	*46.6 %*	*46.3 %*	*47.1 %*
R&D expenses	15	14	15	16	17
SG&A expenses*	52	52	55	56	60
Operating income *	26	30	45	44	58
*Operating margin**	*11.7 %*	*13.5 %*	*18.2 %*	*17.5 %*	*20.2 %*
Other income (expense)	(2)	(0)	(1)	1	(0)
Tax benefit (provision)*	(5)	(6)	(10)	(10)	(12)
Net income*	18	23	35	35	46
*Net income margin**	*8.4 %*	*10.6 %*	*14.0 %*	*14.0 %*	*15.9 %*
Diluted Non-GAAP EPS - Continuing Ops*	0.25	0.32	0.47	0.47	0.61
Adjusted EBITDA*	35	40	54	58	71

© 2021 Brooks Automation, Inc. • Proprietary Information
* Non-GAAP financial measure

Non-GAAP Quarterly Operating Performance – Business Segments Continuing Operations

$ millions

	Brooks Semiconductor Solutions				
	Q2'20	**Q3'20**	**Q4'20**	**Q1'21**	**Q2'21**
Revenue	125	127	138	131	157
Gross profit*	49	54	60	56	70
*Gross profit margin**	*39.5 %*	*42.7 %*	*43.6 %*	*42.8 %*	*44.4 %*
Operating expenses	33	31	32	35	36
Operating income *	17	23	28	22	33
*Operating margin**	*13.4 %*	*18.4 %*	*20.2 %*	*16.4 %*	*21.2 %*
Adjusted EBITDA*	21	27	31	27	39

	Brooks Life Sciences				
	Q2'20	**Q3'20**	**Q4'20**	**Q1'21**	**Q2'21**
Revenue	95	93	108	118	130
Gross profit*	44	42	55	59	65
*Gross profit margin**	*45.8 %*	*44.6 %*	*50.5 %*	*50.2 %*	*50.5 %*
Operating expenses	36	35	37	37	41
Operating income *	8	7	18	22	25
*Operating margin**	*8.5 %*	*7.1 %*	*16.2 %*	*18.8 %*	*19.0 %*
Adjusted EBITDA*	14	13	24	30	33

© 2021 Brooks Automation, Inc. • Proprietary Information
* Non-GAAP financial measure

GAAP to Non-GAAP Reconciliation
Total Brooks – Continuing Operations

$ millions, except EPS

	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY15	FY16	FY17	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Revenue	**220.2**	**220.4**	**246.2**	**249.5**	**286.6**	**406.9**	**434.0**	**527.5**	**631.6**	**780.8**	**897.3**	**833.8**	**1,002.6**
GAAP gross profit	**90.3**	**92.8**	**112.0**	**113.1**	**127.3**	**132.8**	**156.7**	**198.9**	**246.1**	**316.3**	**380.0**	**338.9**	**445.2**
Gross profit margin	*41.0%*	*42.1%*	*45.5%*	*45.3%*	*44.4%*	*32.6%*	*36.1%*	*37.7%*	*39.0%*	*40.5%*	*42.4%*	*40.6%*	*44.4%*
Merger and acquisition costs	-	-	-	-	-	1.5	0.6	0.5	1.9	0.2	-	-	-
Amortization expense	2.7	2.8	2.8	2.4	2.3	4.4	4.0	3.9	4.9	10.4	11.0	11.0	10.3
Tariff adjustment	-	-	-	-	5.5	-	4.0	3.9	-	-	-	-	5.5
Restructuring related charges	-	0.3	-	-	-	-	-	-	-	0.3	0.3	0.3	0.3
Non-GAAP gross profit	**93.0**	**95.9**	**114.8**	**115.5**	**135.1**	**138.7**	**161.3**	**203.3**	**252.9**	**327.2**	**391.3**	**350.3**	**461.3**
Non-GAAP gross profit margin	*42.2%*	*43.5%*	*46.6%*	*46.3%*	*47.1%*	*34.1%*	*37.2%*	*38.5%*	*40.0%*	*41.9%*	*43.6%*	*42.0%*	*46.0%*
GAAP operating expenses	**(75.7)**	**(73.7)**	**(77.8)**	**(82.2)**	**(96.8)**	**(155.3)**	**(173.7)**	**(184.6)**	**(214.7)**	**(270.2)**	**(301.6)**	**(286.7)**	**(330.5)**
Merger and acquisition costs	0.3	0.0	0.0	3.0	11.8	0.7	3.4	8.3	6.9	6.7	0.5	0.8	14.9
Amortization expense	7.6	7.6	7.6	7.4	7.6	7.7	10.8	13.2	19.3	24.7	30.8	27.9	30.2
Restructuring charges	0.6	(0.0)	0.2	0.1	0.1	4.9	10.2	3.1	0.7	1.9	1.4	2.6	0.4
Other special charges	-	-	-	-	-	-	1	-	-	-	-	-	-
Non-GAAP operating expenses	**(67.2)**	**(66.1)**	**(70.0)**	**(71.8)**	**(77.2)**	**(142.1)**	**(148.6)**	**(159.9)**	**(187.7)**	**(236.9)**	**(268.9)**	**(255.4)**	**(285.1)**
GAAP operating profit	**14.6**	**19.1**	**34.1**	**30.9**	**30.5**	**(22.6)**	**(17.1)**	**14.3**	**31.4**	**46.0**	**78.5**	**52.3**	**114.7**
Operating profit margin	*6.6%*	*8.7%*	*13.9%*	*12.4%*	*10.6%*	*-5.5%*	*-3.9%*	*2.7%*	*5.0%*	*5.9%*	*8.7%*	*6.3%*	*11.4%*
Non-GAAP operating profit	**25.8**	**29.8**	**44.8**	**43.8**	**57.9**	**(3.4)**	**12.7**	**43.4**	**65.2**	**90.2**	**122.4**	**94.9**	**176.2**
Non-GAAP operating profit margin	*11.7%*	*13.5%*	*18.2%*	*17.5%*	*20.2%*	*-0.8%*	*2.9%*	*8.2%*	*10.3%*	*11.6%*	*13.6%*	*11.4%*	*17.6%*
GAAP net income	**9.2**	**13.7**	**29.0**	**27.0**	**23.9**	**(12.5)**	**(85.5)**	**10.7**	**67.8**	**9.6**	**65.0**	**28.5**	**93.6**
Merger and acquisition costs	0.3	0.0	0.0	3.0	11.8	2.2	4.0	8.8	8.8	6.9	0.5	0.8	14.9
Amortization expense	10.4	10.4	10.4	9.7	9.9	12.1	14.8	17.1	24.2	35.2	41.8	38.9	40.5
Restructuring charges	0.6	0.3	0.2	0.1	0.1	4.9	10.2	3.1	0.7	1.9	1.7	2.9	0.7
Other special charges	-	-	-	-	-	2.8			(0.1)		-	-	-
Tariff adjustment	-	-	-	-	5.5	-	0.5	(1.5)	-	-	-	-	5.5
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-	14.3	-	5.3	-
Tax related adjustments	1.0	1.5	(0.8)	(2.0)	0.6	(0.2)	76.5	(4.0)	(43.7)	0.3	(3.5)	0.8	(0.7)
Tax effect of adjustments	(3.0)	(2.6)	(4.4)	(2.9)	(6.2)	(5.9)	(6.0)	(3.1)	(12.5)	(13.1)	(12.6)	(10.9)	(16.1)
Non-GAAP net income	**18.5**	**23.3**	**34.5**	**35.0**	**45.6**	**3.4**	**14.6**	**31.2**	**45.3**	**55.0**	**92.9**	**66.3**	**138.4**
Diluted earnings per share	*0.12*	*0.19*	*0.39*	*0.36*	*0.32*	*(0.18)*	*(1.25)*	*0.15*	*0.95*	*0.13*	*0.88*	*0.39*	*1.26*
Non-GAAP diluted earnings per share	*0.25*	*0.32*	*0.47*	*0.47*	*0.61*	*0.05*	*0.21*	*0.44*	*0.64*	*0.76*	*1.26*	*0.91*	*1.87*

© 2021 Brooks Automation, Inc. • Proprietary Information

GAAP to Non-GAAP Reconciliation
Business Segments – Continuing Operations

$ millions

	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Semiconductor Solutions										
Revenue	**124.9**	**127.1**	**137.9**	**131.4**	**157.1**	**435.0**	**446.7**	**508.7**	**464.8**	**553.4**
GAAP gross profit	**48.6**	**53.5**	**59.4**	**55.8**	**69.4**	**174.0**	**181.7**	**207.9**	**184.7**	**238.2**
Gross profit margin	*38.9%*	*42.1%*	*43.1%*	*42.5%*	*44.2%*	*40.0%*	*40.7%*	*40.9%*	*39.7%*	*43.0%*
Amortization expense	0.7	0.7	0.7	0.4	0.3	3.4	3.6	2.9	3.2	2.1
Non-GAAP gross profit	**49.4**	**54.2**	**60.2**	**56.2**	**69.7**	**178.1**	**185.4**	**210.8**	**187.9**	**240.3**
Non-GAAP gross profit margin	*39.5%*	*42.7%*	*43.6%*	*42.8%*	*44.4%*	*40.9%*	*41.5%*	*41.4%*	*40.4%*	*43.4%*
Operating expenses	**(32.7)**	**(30.8)**	**(32.3)**	**(34.6)**	**(36.4)**	**(115.6)**	**(115.5)**	**(127.9)**	**(122.4)**	**(134.2)**
GAAP operating profit	**16.0**	**22.7**	**27.1**	**21.2**	**33.0**	**58.4**	**66.2**	**80.0**	**62.3**	**104.0**
Operating profit margin	*12.8%*	*17.9%*	*19.6%*	*16.1%*	*21.0%*	*13.4%*	*14.8%*	*15.7%*	*13.4%*	*18.8%*
Non-GAAP operating profit	**16.7**	**23.4**	**27.8**	**21.5**	**33.3**	**62.5**	**70.0**	**82.9**	**65.5**	**106.1**
Non-GAAP operating profit margin	*13.4%*	*18.4%*	*20.2%*	*16.4%*	*21.2%*	*14.4%*	*15.7%*	*16.3%*	*14.1%*	*19.2%*
Life Sciences										
Revenue	**95.3**	**93.3**	**108.2**	**118.1**	**129.5**	**196.5**	**334.2**	**388.5**	**369.0**	**449.2**
Gross profit	**41.7**	**39.3**	**52.5**	**57.3**	**57.9**	**72.1**	**134.6**	**172.1**	**154.3**	**207.0**
Gross profit margin	*43.7%*	*42.1%*	*48.5%*	*48.5%*	*44.7%*	*36.7%*	*40.3%*	*44.3%*	*41.8%*	*46.1%*
Amortization expense	2.0	2.1	2.1	2.0	2.0	1.5	6.8	8.1	7.8	8.2
Tariff adjustment	-	-	-	-	5.5		-	-	-	5.5
Restructuring related charges	-	0.3	-	-	-	-	0.3	0.3	0.3	0.3
Non-GAAP gross profit	**43.7**	**41.6**	**54.6**	**59.3**	**65.4**	**74.8**	**141.7**	**180.5**	**162.4**	**221.0**
Non-GAAP gross profit margin	*45.8%*	*44.6%*	*50.5%*	*50.2%*	*50.5%*	*38.0%*	*42.4%*	*46.5%*	*44.0%*	*49.2%*
Operating expenses	**(35.6)**	**(35.0)**	**(37.1)**	**(37.1)**	**(40.8)**	**(71.0)**	**(121.1)**	**(142.4)**	**(135.3)**	**(150.0)**
Operating profit	**6.1**	**4.2**	**15.4**	**20.2**	**17.1**	**1.2**	**13.5**	**29.8**	**18.9**	**57.0**
Operating profit margin	*6.4%*	*4.5%*	*14.2%*	*17.1%*	*13.2%*	*0.6%*	*4.0%*	*7.7%*	*5.1%*	*12.7%*
Non-GAAP operating profit	**8.1**	**6.6**	**17.5**	**22.3**	**24.6**	**3.8**	**20.6**	**38.2**	**27.0**	**71.0**
Non-GAAP operating profit margin	*8.5%*	*7.1%*	*16.2%*	*18.8%*	*19.0%*	*1.9%*	*6.2%*	*9.8%*	*7.3%*	*15.8%*

© 2021 Brooks Automation, Inc. • Proprietary Information

GAAP to Non-GAAP Reconciliation
Segments – Continuing Operations

$ millions

	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Life Sciences Products										
Revenue	**31.0**	**30.4**	**38.6**	**45.5**	**52.4**	**106.1**	**119.0**	**129.8**	**120.8**	**166.9**
GAAP gross profit	**13.4**	**13.3**	**16.7**	**20.5**	**24.1**	**36.2**	**43.6**	**55.7**	**48.1**	**74.5**
Gross profit margin	*43.2%*	*43.6%*	*43.2%*	*45.1%*	*45.9%*	*34.1%*	*36.6%*	*42.9%*	*39.8%*	*44.7%*
Amortization expense	0.3	0.3	0.3	0.3	0.3	1.5	1.2	1.2	1.2	1.1
Non-GAAP gross profit	**13.7**	**13.5**	**17.0**	**20.8**	**24.3**	**38.9**	**44.8**	**56.9**	**49.3**	**75.7**
Non-GAAP gross profit margin	*44.1%*	*44.5%*	*44.0%*	*45.7%*	*46.5%*	*36.6%*	*37.7%*	*43.8%*	*40.8%*	*45.3%*
Operating expenses	**(11.5)**	**(11.1)**	**(12.6)**	**(12.9)**	**(13.1)**	**(47.9)**	**(46.6)**	**(47.5)**	**(47.0)**	**(49.7)**
GAAP operating profit	**1.9**	**2.2**	**4.1**	**7.7**	**10.9**	**(11.7)**	**(3.1)**	**8.2**	**1.1**	**24.9**
Operating profit margin	*6.0%*	*7.2%*	*10.5%*	*16.9%*	*20.9%*	*-11.0%*	*-2.6%*	*6.3%*	*0.9%*	*14.9%*
Non-GAAP operating profit	**2.1**	**2.5**	**4.4**	**7.9**	**11.2**	**(9.0)**	**(1.8)**	**9.4**	**2.3**	**26.0**
Non-GAAP operating profit margin	*6.9%*	*8.2%*	*11.3%*	*17.5%*	*21.4%*	*-8.5%*	*-1.5%*	*7.2%*	*1.9%*	*15.6%*
Life Sciences Services										
Revenue	**64.3**	**62.9**	**69.6**	**72.6**	**77.2**	**90.4**	**215.2**	**258.8**	**248.2**	**282.3**
GAAP gross profit	**28.3**	**26.0**	**35.8**	**36.8**	**33.8**	**35.9**	**91.0**	**116.4**	**106.2**	**132.5**
Gross profit margin	*44.0%*	*41.4%*	*51.5%*	*50.7%*	*43.8%*	*39.7%*	*42.3%*	*45.0%*	*42.8%*	*46.9%*
Amortization expense	1.7	1.8	1.8	1.7	1.7	-	5.6	6.9	6.6	7.0
Tariff adjustment	-	-	-	-	5.5			-	-	5.5
Restructuring related charges	-	0.3	-	-	-	-	0.3	0.3	0.3	0.3
Non-GAAP gross profit	**30.0**	**28.1**	**37.6**	**38.5**	**41.1**	**35.9**	**96.9**	**123.7**	**113.1**	**145.3**
Non-GAAP gross profit margin	*46.7%*	*44.7%*	*54.0%*	*53.1%*	*53.2%*	*39.7%*	*45.0%*	*47.8%*	*45.6%*	*51.5%*
Operating expenses	**(24.0)**	**(24.0)**	**(24.5)**	**(24.2)**	**(27.6)**	**(23.0)**	**(74.4)**	**(94.8)**	**(88.4)**	**(100.3)**
GAAP operating profit	**4.2**	**2.0**	**11.4**	**12.6**	**6.2**	**12.8**	**16.6**	**21.6**	**17.8**	**32.1**
Operating profit margin	*6.6%*	*3.2%*	*16.3%*	*17.3%*	*8.0%*	*14.2%*	*7.7%*	*8.3%*	*7.2%*	*11.4%*
Non-GAAP operating profit	**6.0**	**4.1**	**13.1**	**14.3**	**13.4**	**12.8**	**22.5**	**28.8**	**24.8**	**45.0**
Non-GAAP operating profit margin	*9.3%*	*6.5%*	*18.9%*	*19.7%*	*17.4%*	*14.2%*	*10.4%*	*11.1%*	*10.0%*	*15.9%*

© 2021 Brooks Automation, Inc. • Proprietary Information

Net Income Reconciliation to Adjusted EBITDA Continuing Operations

$ millions

	Q2'20	Q3'20	Q4'20	Q1'21	Q2'21	FY'15	FY'16	FY'17	FY'18	FY'19	FY'20	LTM 3/31/20	LTM 3/31/21
Net income (loss) attributable to Brooks Automation, Inc.	9.1	13.7	29.0	26.0	23.7	14.2	(69.5)	62.6	116.6	437.4	64.9	441.8	92.4
(Income) loss from discontinued operations, net of tax	0.1	-	0.0	1.0	0.2	(26.7)	(16.0)	(51.9)	(48.7)	(427.9)	0.2	(413.3)	1.2
Net income (loss) from continuing operations	**9.2**	**13.7**	**29.0**	**27.0**	**23.9**	**(12.5)**	**(85.5)**	**10.7**	**67.8**	**9.6**	**65.0**	**28.5**	**93.6**
Adjustments:													
Interest income	(0.1)	(0.0)	0.0	(0.1)	(0.0)	(0.9)	(0.5)	(0.5)	(1.9)	(1.4)	(0.8)	(1.5)	(0.1)
Interest expense	0.7	0.8	0.7	0.6	0.5	0.4	0.2	0.4	9.5	22.2	2.9	10.4	2.5
Income tax provision (benefit)	3.4	5.1	4.4	4.8	6.3	(11.3)	66.3	3.4	(47.3)	(0.1)	9.9	7.2	20.6
Depreciation	6.2	6.3	5.3	6.0	5.9	11.4	12.2	10.4	12.5	19.3	23.7	22.3	23.5
Amortization of intangible assets	10.4	10.4	10.4	9.7	9.9	12.1	14.8	17.1	24.2	35.2	41.8	38.9	40.5
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-	14.3	-	5.3	-
EBITDA-from Continuing Operations	**29.8**	**36.3**	**49.8**	**48.0**	**46.5**	**(0.8)**	**7.5**	**41.5**	**64.9**	**99.0**	**142.6**	**111.0**	**180.5**
Non-GAAP adjustments:													
Purchase accounting impact on inventory and contracts acquired	-	-	-	-	-	1.5	0.6	0.5	1.9	0.2	-	-	-
Stock-based compensation	4.2	3.7	4.0	6.7	7.5	11.9	11.3	16.6	18.9	19.5	16.3	18.8	21.9
Tariff adjustment					5.5	-	-	-	-	-	-	-	5.5
Restructuring	0.6	(0.0)	0.2	0.1	0.1	4.9	10.2	3.1	0.7	1.9	1.4	2.6	0.4
Restructuring related charges		0.3	-			-	-	-	-	0.3	0.3	0.3	0.3
Merger and acquisition costs / Other	0.3	0.0	0.0	3.0	11.8	0.7	4.2	6.7	6.9	6.7	0.5	0.8	14.9
Adjusted EBITDA - from Continuing Operations	**34.8**	**40.3**	**54.0**	**57.8**	**71.4**	**18.1**	**33.8**	**68.5**	**93.3**	**127.6**	**161.0**	**133.5**	**223.5**

© 2021 Brooks Automation, Inc. • Proprietary Information

Operating Profit Reconciliation to Adjusted EBITDA
Business Segments – Continuing Operations

$ millions

Semiconductor Solutions	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Operating Profit	**16.0**	**22.7**	**27.1**	**21.2**	**33.0**	**58.4**	**66.2**	**80.0**	**62.3**	**104.0**
Non-GAAP adjustments:										
Depreciation	1.7	1.7	0.5	1.3	1.4	4.8	4.2	5.4	5.1	4.9
Amortization of intangible assets	0.7	0.7	0.7	0.4	0.3	3.4	3.6	2.9	3.2	2.1
EBITDA	**18.4**	**25.1**	**28.3**	**22.9**	**34.7**	**66.5**	**74.0**	**88.4**	**70.6**	**111.0**
EBITDA margin	***14.8%***	***19.8%***	***20.5%***	***17.4%***	***22.1%***	***15.3%***	***16.6%***	***17.4%***	***15.2%***	***20.0%***
Stock-based compensation	2.7	2.1	2.2	3.9	4.1	13.2	12.7	9.9	12.2	12.3
Adjusted EBITDA	**21.1**	**27.2**	**30.6**	**26.7**	**38.8**	**80.6**	**87.0**	**98.3**	**82.8**	**123.2**
Adjusted EBITDA margin	***16.9%***	***21.4%***	***22.2%***	***20.3%***	***24.7%***	***18.5%***	***19.5%***	***19.3%***	***17.8%***	***22.3%***

Total Life Sciences	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Operating Profit	**6.1**	**4.2**	**15.4**	**20.2**	**17.1**	**1.2**	**13.5**	**29.8**	**18.9**	**57.0**
Non-GAAP adjustments:										
Depreciation	4.5	4.6	4.8	4.7	4.5	16.8	16.9	18.3	17.6	18.6
Amortization & restructuring related	2.0	2.4	2.1	2.0	2.0	1.5	7.1	8.4	8.1	8.5
EBITDA	**12.6**	**11.2**	**22.3**	**26.9**	**23.6**	**19.4**	**37.5**	**56.5**	**44.7**	**84.1**
EBITDA margin	***13.3%***	***12.0%***	***20.6%***	***22.8%***	***18.2%***	***9.9%***	***11.2%***	***14.5%***	***12.1%***	***18.7%***
Tariffs	-	-	-	-	5.5	-	-	-	-	5.5
Stock-based compensation	1.5	1.6	1.7	2.8	3.4	5.7	6.8	6.4	6.6	9.6
Adjusted EBITDA	**14.2**	**12.8**	**24.0**	**29.8**	**32.5**	**26.3**	**44.3**	**62.9**	**51.3**	**99.2**
Adjusted EBITDA margin	***14.9%***	***13.7%***	***22.2%***	***25.2%***	***25.1%***	***13.4%***	***13.3%***	***16.2%***	***13.9%***	***22.1%***

© 2021 Brooks Automation, Inc. • Proprietary Information

Operating Profit Reconciliation to Adjusted EBITDA
Segments – Continuing Operations

$ millions

Life Science Products	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Operating Profit (loss)	**1.9**	**2.2**	**4.1**	**7.7**	**10.9**	**(11.7)**	**(3.1)**	**8.2**	**1.1**	**24.9**
Non-GAAP adjustments:										
Depreciation	0.8	0.8	0.8	0.8	0.9	2.9	3.0	3.3	3.1	3.4
Amortization of intangible assets	0.3	0.3	0.3	0.3	0.3	1.5	1.2	1.2	1.2	1.1
EBITDA	**2.9**	**3.3**	**5.2**	**8.8**	**12.1**	**(7.3)**	**1.1**	**12.6**	**5.4**	**29.4**
EBITDA margin	***9.5%***	***10.9%***	***13.4%***	***19.3%***	***23.2%***	***-6.9%***	***0.9%***	***9.7%***	***4.5%***	***17.6%***
Stock-based compensation	0.3	0.5	0.6	0.9	1.2	4.4	3.6	2.2	2.7	3.3
Adjusted EBITDA	**3.2**	**3.9**	**5.8**	**9.7**	**13.3**	**(1.8)**	**4.8**	**14.9**	**8.1**	**32.7**
Adjusted EBITDA margin	***10.4%***	***12.7%***	***15.1%***	***21.4%***	***25.4%***	***-1.7%***	***4.0%***	***11.5%***	***6.7%***	***19.6%***

Life Science Services	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	Q2 FY21	FY18	FY19	FY20	LTM 3/31/20	LTM 3/31/21
Operating Profit	**4.2**	**2.0**	**11.4**	**12.6**	**6.2**	**12.8**	**16.6**	**21.6**	**17.8**	**32.1**
Non-GAAP adjustments:										
Depreciation	3.7	3.8	4.0	3.8	3.6	13.9	14.0	15.0	14.5	15.2
Amortization & restructuring related	1.7	2.1	1.8	1.7	1.7	-	5.9	7.2	6.9	7.3
EBITDA	**9.7**	**7.9**	**17.1**	**18.1**	**11.5**	**26.7**	**36.4**	**43.8**	**39.3**	**54.6**
EBITDA margin	***15.1%***	***12.5%***	***24.6%***	***25.0%***	***14.9%***	***29.5%***	***16.9%***	***16.9%***	***15.8%***	***19.4%***
Tariffs	-	-	-	-	5.5	-	-	-	-	5.5
Stock-based compensation	1.2	1.1	1.1	1.9	2.2	1.3	3.1	4.2	3.9	6.3
Adjusted EBITDA	**11.0**	**9.0**	**18.2**	**20.1**	**19.2**	**28.0**	**39.5**	**48.0**	**43.1**	**66.4**
Adjusted EBITDA margin	***17.0%***	***14.2%***	***26.2%***	***27.6%***	***24.9%***	***31.0%***	***18.4%***	***18.5%***	***17.4%***	***23.5%***

© 2021 Brooks Automation, Inc. • Proprietary Information